Exelixis (EXEL) Cash & Current Investments (2010 - 2026)
Exelixis (EXEL) posted quarterly Cash & Current Investments of $777.2 million for Q2 2026, down 24.64% year-over-year from $1.0 billion in Q2 2025, and down 26.62% quarter-over-quarter from $1.1 billion in Q1 2026.
Analysis
Exelixis (EXEL) Cash & Current Investments (2010 - 2026) Analysis & Trends
Exelixis' Cash & Current Investments history runs 17 years deep, the most recent figure standing at $777.2 million for Q2 2026.
- In Q2 2026, Cash & Current Investments fell 24.64% year-over-year to $777.2 million; the TTM figure through Apr 2026 stood at $777.2 million (down 24.64% YoY), while the FY2026 annual figure was $1.1 billion, down 4.7% from the prior year.
- Cash & Current Investments for Q2 2026 stood at $777.2 million, down from $1.1 billion in the prior quarter.
- The five-year high for Cash & Current Investments was $1.6 billion in Q2 2022, with the low at $777.2 million in Q2 2026.
- The 5-year median for Cash & Current Investments is $1.1 billion (2023), against an average of $1.2 billion.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments soared 32.46% in 2022, then fell 28.68% in 2023.
- Exelixis' Cash & Current Investments stood at $1.3 billion in 2022, then retreated by 23.93% to $995.3 million in 2023, then advanced by 19.48% to $1.2 billion in 2024, then decreased by 16.87% to $988.5 million in 2025, then slipped by 21.38% to $777.2 million in 2026.
- Business Quant data shows EXEL's Cash & Current Investments at $777.2 million in Q2 2026, $1.1 billion in Q1 2026, and $988.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 839.39 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 839.39 Mn |
| Apr 3, 2026 | 777.21 Mn |
| Jan 2, 2026 | 1.06 Bn |
| Oct 3, 2025 | 988.54 Mn |
| Jul 4, 2025 | 791.10 Mn |
| Apr 4, 2025 | 1.03 Bn |
| Jan 3, 2025 | 1.11 Bn |
| Sep 27, 2024 | 1.19 Bn |
| Jun 28, 2024 | 1.00 Bn |
| Mar 29, 2024 | 963.26 Mn |
| Dec 29, 2023 | 995.30 Mn |
| Sep 29, 2023 | 1.10 Bn |
| Jun 30, 2023 | 1.27 Bn |
| Mar 31, 2023 | 1.31 Bn |
| Dec 30, 2022 | 1.31 Bn |
| Sep 30, 2022 | 1.55 Bn |
| Jul 1, 2022 | 1.53 Bn |
| Apr 1, 2022 | 1.57 Bn |
| Dec 31, 2021 | 1.47 Bn |
| Oct 1, 2021 | 1.40 Bn |